Safety of ABM-1310 in Patients With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This is a Phase I, First-In-Human, open label, dose escalation study to evaluate the safety,
tolerability, pharmacokinetics, and preliminary anti-cancer activity of ABM-1310 in adult
patients with documented BRAF V600 mutation and locally advanced or metastatic solid tumors
who have no effective standard treatment options available, as monotherapy in Part A, or in
combination with cobimetinib (Cotellic®) in Part B in adult patients who also have documented
progressive disease or intolerance to previous combination treatment of BRAF and MEK
inhibitors. A "3+3" design will be used to determine MTD and RP2D.